Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Oral Anticoagulation and Risk of Symptomatic Hemorrhagic Transformation in Stroke Patients Treated With Mechanical Thrombectomy: Data From the Nordictus Registry

  • Ramos-Araque, M.E.
  • Chavarría-Miranda, A.
  • Gómez-Vicente, B.
  • López-Cancio Martínez, E.
  • Castañón Apilánez, M.
  • Castellanos, M.
  • López Fernández, M.
  • Tejada Meza, H.
  • Marta Moreno, J.
  • Tejada García, J.
  • Beltrán Rodríguez, I.
  • de la Riva, P.
  • Díez, N.
  • Arias Rivas, S.
  • Santamaría Cadavid, M.
  • Bravo Anguiano, Y.
  • Bártulos Iglesias, M.
  • Palacio Portilla, E.J.
  • Revilla García, M.
  • Timiraos Fernández, J.J.
  • Arenaza Basterrechea, N.
  • Maciñeiras Montero, J.L.
  • Vicente Alba, P.
  • Julián Villaverde, F.J.
  • Pinedo Brochado, A.
  • Azkune, I.
  • Mar, F.M.
  • Luna, A.
  • Arenillas, J.F.
Introduction: We aimed to evaluate if prior oral anticoagulation (OAC) and its type determines a greater risk of symptomatic hemorrhagic transformation in patients with acute ischemic stroke (AIS) subjected to mechanical thrombectomy. Materials and Methods: Consecutive patients with AIS included in the prospective reperfusion registry NORDICTUS, a network of tertiary stroke centers in Northern Spain, from January 2017 to December 2019 were included. Prior use of oral anticoagulants, baseline variables, and international normalized ratio (INR) on admission were recorded. Symptomatic intracranial hemorrhage (sICH) was the primary outcome measure. Secondary outcome was the relation between INR and sICH, and we evaluated mortality and functional outcome at 3 months by modified Rankin scale. We compared patients with and without previous OAC and also considered the type of oral anticoagulants. Results: About 1.455 AIS patients were included, of whom 274 (19%) were on OAC, 193 (70%) on vitamin K antagonists (VKA), and 81 (30%) on direct oral anticoagulants (DOACs). Anticoagulated patients were older and had more comorbidities. Eighty-one (5.6%) developed sICH, which was more frequent in the VKA group, but not in DOAC group. OAC with VKA emerged as a predictor of sICH in a multivariate regression model (OR, 1.89 [95% CI, 1.01–3.51], p = 0.04) and was not related to INR level on admission. Prior VKA use was not associated with worse outcome in the multivariate regression model nor with mortality at 3 months. Conclusions: OAC with VKA, but not with DOACs, was an independent predictor of sICH after mechanical thrombectomy. This excess risk was associated neither with INR value by the time thrombectomy was performed, nor with a worse functional outcome or mortality at 3 months.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Genome-Wide Association Study of VKORC1 and CYP2C9 on acenocoumarol dose, stroke recurrence and intracranial haemorrhage in Spain

  • Cullell, Natalia|||0000-0001-5118-1014
  • Carrera, Caty|||0000-0002-0804-0969
  • Muiño, Elena|||0000-0001-5839-7328
  • Torres-Aguila, Nuria|||0000-0002-9502-9310
  • Cárcel-Márquez, Jara|||0000-0002-6949-0699
  • González-Sánchez, Jonathan
  • Gallego Fabrega, Cristina|||0000-0003-3229-5512
  • Molina, Jessica
  • Besora, Sarah
  • Sotoca Fernández, Javier|||0000-0003-3400-1434
  • Buongiorno, María-Teresa
  • Jimenez-Conde, Jordi|||0000-0002-2623-6199
  • Giralt Steinhauer, Eva|||0000-0002-7463-0983
  • de Torres-Chacón, Reyes
  • Montaner, Joan|||0000-0003-4845-2279
  • Mancha, Fernando|||0000-0003-0310-0894
  • Cabezas, Juan Antonio
  • Martí-Fàbregas, Joan|||0000-0001-9229-8649
  • Prats Sánchez, Luis Antonio|||0000-0002-3192-4631
  • Camps-Renom, Pol|||0000-0001-6587-6271
  • Purroy, Francisco|||0000-0002-1808-5968
  • Cambray, Serafi
  • Freijo, María del Mar
  • Vives-Bauzá, Cristòfol|||0000-0001-5735-8335
  • Tur, Silvia
  • Font, Maria-Àngels
  • López-Cancio, Elena|||0000-0001-5757-9074
  • Hernández-Pérez, María|||0000-0001-8279-7954
  • Obach, Víctor|||0000-0002-0518-1053
  • Calleja, Ana
  • Arenillas, Juan F.|||0000-0001-7464-6101
  • Rodríguez-Yáñez, Manuel
  • Castillo, José
  • Sobrino, Tomás|||0000-0002-9760-8690
  • Fernández Cadenas, Israel|||0000-0003-4821-2363
  • Krupinski, Jerzy|||0000-0002-5136-8898
Acenocoumarol is an oral anticoagulant with significant interindividual dose variations. Variants in CYP2C9 and VKORC1 have been associated with acenocoumarol maintenance dose. We analysed whether any of the 49 polymorphisms in CYP2C9 and VKORC1 previously associated with acenocoumarol maintenance dose in a Genome-Wide Association study (GWAs) in Dutch population are associated with stroke recurrence, intracranial haemorrhage (ICH) and acenocoumarol maintenance dose in a Spanish population. We performed a GWAs using Human Core Exome-chip (Illumina) in 78 patients stroke patients treated with acenocoumarol for secondary prevention enrolled as part of the prospective investigator-initiated study (IIS) SEDMAN Study. Patients were followed-up a median of 12.8 months. Three and eight patients had recurrent stroke and ICH events, respectively. We found 14 of the 49 published variants associated with acenocoumarol maintenance dose (p < 0.05). Six polymorphisms were associated with stroke recurrence and four variants with ICH (p < 0.05). In conclusion, variants in VKORC1 and CYP2C9 are associated with acenocoumarol maintenance dose, stroke recurrence and ICH in a Spanish cohort. These results highlight the relevance of studying pharmacogenetics associated with efficacy and safety of anticoagulant drugs and justify studies with larger sample size and different ethnic populations.